Acutaas Chemicals has announced its Q3 FY26 financial results, reporting strong growth and profitability. Revenue reached INR393.2 crores, a 43% year-over-year increase, with profit after tax crossing INR100 crores. The company has revised its revenue growth guidance upwards from 25% to around 30% for FY26, driven by a robust order book. A new battery chemicals block was inaugurated in January 2026.
Financial Performance Highlights
Acutaas Chemicals reported a strong financial performance for Q3 FY26, with revenue from operations reaching INR393.2 crores, representing a 43% year-over-year growth. Gross profit for the quarter was INR224 crores, a 76.1% increase compared to the same period last year. The company’s profit after tax (PAT) for the quarter was INR106.2 crores, up 133.7% year-over-year.
Revised Outlook
Based on a strong current order book, Acutaas Chemicals is revising its revenue guidance upwards from 25% to around 30% growth for FY26. The company has also upgraded its EBITDA margin guidance from 28-30% to a range of 32-35% for the full year.
Segmental Performance
The Advanced Pharmaceutical Intermediates segment delivered a strong performance with revenue of INR351.1 crores in Q3 FY26, reflecting a year-on-year growth of 47.0%. The Specialty Chemicals segment revenue stood at INR42.1 crores, registering a year-on-year growth of 16.5%.
Battery Chemicals Expansion
A new block at the Jhagadia facility dedicated exclusively to battery chemicals was inaugurated on January 19, 2026. Commercial operations are expected to ramp up significantly from Q1 FY27. Capex for the project is expected to be around INR220 crores.
Indichem Joint Venture
Acutaas Chemicals has invested close to INR130 crores in the South Korea joint venture, Indichem. The total investment announced for this joint venture was around INR200 crores, with capex progressing as per plan and expected to complete by the end of calendar year 2026, with revenue generation beginning the next calendar year.
CDMO Business
Four products have been validated in the CDMO business and are expected to start contributing to the top line from FY27. The company’s CDMO pipeline continues to grow strongly and the business is projected to reach INR1,000 crores by FY28.
Source: BSE
